Literature DB >> 20142815

Epidemiology and treatment of melanoma in elderly patients.

Susan Tsai1, Charles Balch, Julie Lange.   

Abstract

The number of melanoma cases in the elderly (>65 years) will rise over the coming decades, making it an important public health problem. Elderly white men are the demographic group who are at highest risk of being diagnosed with melanoma and of dying from this cancer. Among patients with melanoma, older age is recognized as an independent poor prognostic factor, but it remains unclear whether this relationship is due to a change in the biology of the disease with increasing patient age, declining host defenses, or both. Most elderly patients can have surgery to control locoregional disease, but might not be candidates for intensive biologic therapies for advanced melanoma because of comorbidities and inability to tolerate the adverse side effects of these treatments. Early detection remains an important strategy for the management of melanoma. Further research is needed to determine why older melanoma patients have a worse prognosis than their younger counterparts, even when matched for all other clinical and pathological predictors of survival outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20142815     DOI: 10.1038/nrclinonc.2010.1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  41 in total

1.  Senile changes in human lymph nodes.

Authors:  Wei-Ren Pan; Hiroo Suami; G Ian Taylor
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

2.  Thick melanoma: the challenge persists.

Authors:  C S Murray; D L Stockton; V R Doherty
Journal:  Br J Dermatol       Date:  2005-01       Impact factor: 9.302

3.  Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy.

Authors:  Janice N Cormier; Yan Xing; Meichun Ding; Jeffrey E Lee; Paul F Mansfield; Jeffrey E Gershenwald; Merrick I Ross; Xianglin L Du
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group.

Authors:  M Vercelli; R Capocaccia; A Quaglia; C Casella; A Puppo; J W Coebergh
Journal:  Crit Rev Oncol Hematol       Date:  2000-09       Impact factor: 6.312

5.  Recent trends in cutaneous melanoma incidence among whites in the United States.

Authors:  A Jemal; S S Devesa; P Hartge; M A Tucker
Journal:  J Natl Cancer Inst       Date:  2001-05-02       Impact factor: 13.506

6.  Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm.

Authors:  G Cohn-Cedermark; L E Rutqvist; R Andersson; M Breivald; C Ingvar; H Johansson; P E Jönsson; L Krysander; C Lindholm; U Ringborg
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

7.  Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics.

Authors:  Jennifer L Schwartz; Timothy S Wang; Ted A Hamilton; Lori Lowe; Vernon K Sondak; Timothy M Johnson
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

8.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

9.  Age-related lymphatic dysfunction in melanoma patients.

Authors:  W Charles Conway; Mark B Faries; Michael B Nicholl; Alicia M Terando; Edwin C Glass; MyungShin Sim; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2009-03-11       Impact factor: 5.344

10.  Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.

Authors:  Florent Grange; Fabien Vitry; Florence Granel-Brocard; Dan Lipsker; Francois Aubin; Guy Hédelin; Sophie Dalac; François Truchetet; Catherine Michel; Marie-Laure Batard; Béatrice Baury; Jean-Michel Halna; Jean Luc Schmutz; Christian Delvincourt; Georges Reuter; Stéphane Dalle; Phillipe Bernard; Arlette Danzon
Journal:  Arch Dermatol       Date:  2008-05
View more
  16 in total

1.  Implications of age and conditional survival estimates for patients with melanoma.

Authors:  Mousumi Banerjee; Christopher D Lao; Lauren M Wancata; Daniel G Muenz; Megan R Haymart; Sandra L Wong
Journal:  Melanoma Res       Date:  2016-02       Impact factor: 3.599

2.  Impact of age on the management of primary melanoma patients.

Authors:  Nathaniel H Fleming; Jiaying Tian; Eleazar Vega-Saenz de Miera; Heidi Gold; Farbod Darvishian; Anna C Pavlick; Russell S Berman; Richard L Shapiro; David Polsky; Iman Osman
Journal:  Oncology       Date:  2013-08-30       Impact factor: 2.935

3.  Age as a prognostic factor in patients with localized melanoma and regional metastases.

Authors:  Charles M Balch; Seng-jaw Soong; Jeffrey E Gershenwald; John F Thompson; Daniel G Coit; Michael B Atkins; Shouluan Ding; Alistair J Cochran; Alexander M M Eggermont; Keith T Flaherty; Phyllis A Gimotty; Timothy M Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2013-07-10       Impact factor: 5.344

4.  Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials.

Authors:  Aminah Jatoi; Jacob B Allred; Vera J Suman; Edward T Creagan; Gary A Croghan; Thomas Amatruda; Svetomir N Markovic
Journal:  J Geriatr Oncol       Date:  2012-05-07       Impact factor: 3.599

5.  Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base.

Authors:  Vijaya Raj Bhatt; Rajesh Shrestha; Jairam Krishnamurthy; Kailash Mosalpuria; Fausto R Loberiza; Apar Kishor Ganti; Peter T Silberstein
Journal:  Ther Adv Med Oncol       Date:  2015-01       Impact factor: 8.168

6.  Responses to immune checkpoint inhibitors in nonagenarians.

Authors:  Romany A N Johnpulle; Robert M Conry; Jeffrey A Sosman; Igor Puzanov; Douglas B Johnson
Journal:  Oncoimmunology       Date:  2016-10-18       Impact factor: 8.110

7.  Increasing Incidence of Melanoma in the Elderly: An Epidemiological Study in Olmsted County, Minnesota.

Authors:  Jeannette M Olazagasti Lourido; Janice E Ma; Christine M Lohse; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2016-09-28       Impact factor: 7.616

8.  Chemotherapy use in stage III colon cancer: a National Cancer Database analysis.

Authors:  Smrity Upadhyay; Sumit Dahal; Vijaya Raj Bhatt; Nabin Khanal; Peter T Silberstein
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

Review 9.  Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.

Authors:  Aljosja Rogiers; Joost J van den Oord; Marjan Garmyn; Marguerite Stas; Cindy Kenis; Hans Wildiers; Jean-Christophe Marine; Pascal Wolter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

10.  Association of Delays in Surgery for Melanoma With Insurance Type.

Authors:  Adewole S Adamson; Lei Zhou; Christopher D Baggett; Nancy E Thomas; Anne-Marie Meyer
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.